Alterations in the immune system persist after one year of convalescence in severe COVID-19 patients

Introduction Severe COVID-19 originates a myriad of alterations in the immune system during active disease, especially in the T and NK cell compartments, but several studies in the last year have unveiled some alterations that persist in convalescence. Although most of the studies follow the participants for a short recovery time, studies following patients up to three or six months still find alterations. We aimed at evaluating changes in the NK, T and B cell compartments after severe COVID-19 in participants with a median recovery time of eleven months. Methods Eighteen convalescent of severe COVID-19 (CSC), 14 convalescent of mild COVID-19 (CMC) and nine controls were recruited. NKG2A, NKG2C, NKG2D and the activating receptor NKp44 were evaluated in NKbright, NKdim and NKT subpopulations. In addition, CD3 and CD19 were measured and a basic biochemistry with IL-6 levels was obtained. Results CSC participants showed lower NKbright/NKdim ratio, higher NKp44 expression in NKbright subpopulations, higher levels of serum IL-6, lower levels of NKG2A+ T lymphocytes and a trend to a lower expression of CD19 in B lymphocytes compared to controls. CMC participants showed no significant alterations in the immune system compared to controls. Conclusions These results are concordant with previous studies, which find alterations in CSC weeks or months after resolution of the symptoms, and point to the possibility of these alterations lasting one year or more after COVID-19 resolution.

[1]  S. Della Bella,et al.  Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications , 2022, Frontiers in Immunology.

[2]  L. Joosten,et al.  Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19 , 2022, Frontiers in Immunology.

[3]  Tao Jiang,et al.  Identification of Distinct Immune Cell Subsets Associated With Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 Patients , 2022, Frontiers in Immunology.

[4]  E. Mace Profiling natural killers in COVID-19 , 2022, Journal of Allergy and Clinical Immunology.

[5]  A. Antón,et al.  COVID-19 Clinical Profile in Latin American Migrants Living in Spain: Does the Geographical Origin Matter? , 2021, Journal of clinical medicine.

[6]  Haiyoung Jung,et al.  SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity , 2021, Cellular Immunology.

[7]  E. Bargagli,et al.  NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19 , 2021, Cells.

[8]  S. Jiménez,et al.  Increased severity in SARS-CoV-2 infection of minorities in Spain , 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[9]  M. Kubo,et al.  SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism , 2021, Signal Transduction and Targeted Therapy.

[10]  S. Barry,et al.  Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection , 2021, BMC Medicine.

[11]  Héctor Martínez Alonso,et al.  Socio-Demographic Health Determinants Are Associated with Poor Prognosis in Spanish Patients Hospitalized with COVID-19 , 2021, Journal of General Internal Medicine.

[12]  P. Kaminski,et al.  Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases , 2021, Cells.

[13]  Baoju Wang,et al.  Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment , 2021, mBio.

[14]  A. Douiri,et al.  COVID-19 and ethnicity:has history repeated itself? , 2021, Thorax.

[15]  C. Brightling,et al.  Alterations in T and B cell function persist in convalescent COVID-19 patients , 2021, Med.

[16]  R. López-Vélez,et al.  COVID-19 and geographical area of origin , 2020, Clinical Microbiology and Infection.

[17]  F. Fathi,et al.  Immune system changes during COVID-19 recovery play key role in determining disease severity , 2020, International journal of immunopathology and pharmacology.

[18]  B. Reinius,et al.  Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.

[19]  G. Jiang,et al.  Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus , 2020, Clinical Rheumatology.

[20]  E. Malmierca,et al.  Epidemiological characteristics of the COVID-19 outbreak in a secondary hospital in Spain , 2020, American Journal of Infection Control.

[21]  F. Zheng,et al.  The Increased Ratio of Blood CD56bright NK to CD56dim NK Is a Distinguishing Feature of Primary Sjögren's Syndrome , 2020, Journal of immunology research.

[22]  J. Mikes,et al.  Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 , 2020, Cell Reports Medicine.

[23]  C. Pellegrini,et al.  NKG2A and COVID-19: another brick in the wall , 2020, Cellular & Molecular Immunology.

[24]  Antonio Uccelli,et al.  CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis , 2020, Journal of clinical medicine.

[25]  R. Bruno,et al.  Unique immunological profile in patients with COVID-19 , 2020, Cellular & Molecular Immunology.

[26]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[27]  Z. Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[28]  H. Favoreel,et al.  NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans , 2019, Front. Immunol..

[29]  H. Hocine,et al.  Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes , 2015, Nature Communications.

[30]  T. Mak,et al.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity , 2011, Proceedings of the National Academy of Sciences.

[31]  R. Welsh,et al.  Natural killer cells act as rheostats modulating antiviral T cells , 2011, Nature.

[32]  P. J. Norris,et al.  Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection , 2011, Proceedings of the National Academy of Sciences.

[33]  H. Ljunggren,et al.  Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus , 2011, The Journal of experimental medicine.

[34]  A. Angulo,et al.  IL-12-Dependent Inducible Expression of the CD94/NKG2A Inhibitory Receptor Regulates CD94/NKG2C+ NK Cell Function1 , 2009, The Journal of Immunology.

[35]  J. R. Lapa e Silva,et al.  Another brick in the wall. , 2002, Sao Paulo medical journal = Revista paulista de medicina.